NK 5807

Drug Profile

NK 5807

Alternative Names: NK5807

Latest Information Update: 21 Aug 2007

Price : $50

At a glance

  • Originator Nippon Kayaku
  • Class Antiasthmatics; Naphthyridines
  • Mechanism of Action Neurokinin 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 18 Dec 2003 No development reported - Preclinical for Asthma in Japan (unspecified route)
  • 28 Mar 2001 NK 5807 is available for licensing (http://www.tokyoweb.or.jp/NIPPONKAYAKU/)
  • 28 Mar 2001 Preclinical development for Asthma in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top